Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Biomarin Pharmaceut (BMRN)

87.61 -1.75 (-1.96%)

05-22 16:00

Open:

87

Pre. Close:

89.36

High:

88.18

Low:

84.02

Volume:

3,432,453

Market Cap:

15482M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

88.283 - 88.748

88.748 - 89.144

Low:

82.945 - 83.459

83.459 - 83.896

Close:

86.737 - 87.639

87.639 - 88.407

Technical analysis  (as of: 2018-05-22 4:37:07 PM)

Overall:

      

Stoxline posted a SELL today, downgraded from higher rating. This stock seems to be ready for a new bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.

Target:

Six months: 106.11     One year: 123.94

Support:

Support1: 84.16    Support2: 80.03

Resistance:

Resistance1: 90.85    Resistance2: 106.11

Pivot:

87.48

Moving Averages:

MA(5): 88.76     MA(20): 86.51

MA(100): 85.19     MA(250): 87.00

MACD:

MACD(12,26): 1.67     Signal(12,26,9): 1.65

%K %D:

%K(14,3): 77.90     %D(3): 82.00

RSI:

RSI(14): 54.66

52-Week:

High: 100.03  Low: 75.81  Change(%): -0.5

Average Vol(K):

3-Month: 133594  10-Days 137961

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
BMRN has closed below upper band by 48.5%. Bollinger Bands are 8.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2018-05-22T08:09:53-04:00
BioMarin's valoctocogene roxaparvovec shows long-term treatment effect in hemophilia A study

2018-05-22T07:30:00-04:00
BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018 World Congress

2018-05-18T16:37:17-04:00
Key events next week - healthcare

2018-05-17T16:05:00-04:00
BioMarin Announces 1 Platform and 3 Poster Presentations at World Federation of Hemophilia 2018 World Congress

2018-05-16T07:56:53-04:00
Premarket analyst action - healthcare

2018-05-15T09:29:16-04:00
BioMarin starts Phase 1/2 study of gene therapy for hemophilia A subgroup

2018-05-15T08:30:00-04:00
BioMarin Announces First Patient Dosed in Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec Gene Therapy in Severe Hemophilia A Patients with Pre-existing AAV5 Antibodies

2018-05-11T07:38:21-04:00
FANG Stocks Have Ignited A Rally - Cramer's Mad Money (5/10/18)

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Biopharmaceuticals

Shares Out. (M)

176.71

Shares Float (M)

175.12

% Held by Insiders

0.90

% Held by Institutions

Shares Short (K)

12119

Shares Short Prior Month (K)

8190

Stock Financials

EPS

-0.500

EPS Est. Current Year

-0.740

EPS Est. Next Year

-0.240

EPS Est. Next Quarter

-0.150

Forward EPS

0.210

Book Value (p.s.)

5.630

PEG Ratio

-1.84

Profit Margin

-10.83

Operating Margin

-10.37

Return on Assets (ttm)

-3.4

Return on Equity (ttm)

-5.2

Qtrly Rev. Growth

22.9

Gross Profit (p.s.)

3.032

Sales Per Share

EBITDA (p.s.)

-0.075

Qtrly Earnings Growth

Operating Cash Flow (M)

29.18

Levered Free Cash Flow (M)

19.09

atoplab.com

Valuation

P/E

-175.22

P/E Growth Ratio

-0.02

P/BV

15.56

P/S

1962175360.00

P/CF

530.56

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.